Info

Diabetes Connections | Type 1 Diabetes

The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
RSS Feed Subscribe in Apple Podcasts
Diabetes Connections | Type 1 Diabetes
2024
March
February
January


2023
December
November
October
September
August
July
June
May
April
March
February
January


2022
December
November
October
September
August
July
June
May
April
March
February
January


2021
December
November
October
September
August
July
June
May
April
March
February
January


2020
December
November
October
September
August
July
June
May
April
March
February
January


2019
December
November
October
September
August
July
June
May
April
March
February
January


2018
December
November
October
September
August
July
June
May
April
March
February
January


2017
December
November
October
September
August
July
June
May
April
March
February
January


2016
December
November
October
September
August
July
June
May
April
March
February
January


2015
December
November
October
September
August
July
June
May


Categories

All Episodes
Archives
Categories
Now displaying: October, 2022
Oct 25, 2022

The author of Six Until Me, Kerri Sparling, isn’t blogging any more, but she’s still looking for stories of connection and community built around conversation

For 14 years Kerri wrote a daily blog about her experience with type 1. She put aside SixUntilMe in 2019. We’re going to talk about her new book, what she thinks about the online community these days and what’s next.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Oct 21, 2022

It’s It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: a troubling new study about how many people with diabetes ration insulin, a new study looks at OpenAPS compared to traditional pumps, more research on Beta Bionics' iLet pump, an old diabetes drug might help in the fight against dementia, and more!

Learn more about the T1D Exchange: https://t1dexchange.org/stacey/

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
A new study shows nearly 1 in 5 adults in the U.S. with diabetes either skipped, delayed or used less insulin than was needed to save money. That comes out to roughly 1.3 million adults, or 16.5% of those who need insulin. The findings were based on data from the 2021 National Health Interview Survey, which is conducted annually by the Centers for Disease Control and Prevention and which interviews tens of thousands of Americans about their health-related experiences. It was the first time that the CDC had included questions about insulin use, though concerns about sky-high insulin prices have been reported for years.
Starting Jan. 1, the Inflation Reduction Act, signed into law by President Joe Biden in August, will cap the monthly cost of insulin at $35 for seniors on Medicare. The bill, however, will leave out millions of Americans with private health insurance as well as those who are uninsured. It was also found to be more common among people with type 1 diabetes, at 18.6%, compared to those with type 2 diabetes, at 15.8%
https://www.nbcnews.com/health/health-news/insulin-prices-many-adults-diabetes-ration-insulin-study-finds-rcna52287?cid=sm_npd_nn_tw_ma
XX
New islet cell transplant study looks very promising. Long term outcomes of two phase 3 clinical trials shows many patients didn’t need insulin to maintain their blood sugar for up to eight years. It also showed that a new approach required fewer transplants than typical and was exceedingly safe. These trials included people who had kidney transplants and showed islet cell transplants for those people was safe and effective.
75 percent who initially were able to come off insulin therapy, more than half maintained total insulin independence, meaning they needed no additional insulin injections throughout the years of follow-up.

https://www.pennmedicine.org/news/news-releases/2022/october/new-islet-transplant-method-leads-to-insulin-independence
XX
Study out of New Zealand looked at DIY diabetes tech and compared to some commercial offerings. Not sure what they were tyring to prvoe here because they looked at a closed loop system OpenAPS and compared it to a regular old pump and CGM system with no automation. No surprisingly, the people with type 1 in the AID group had much more time in range – about 14 percent more – than those using a standalone pump and CGM. No severe lows or DKA in either group. But these days, IMO, looking at an automated insulin delivery system to a pump and CGM that don’t communicate is like comparing apples and chain saws.

https://www.medtechdive.com/news/do-it-yourself-artificial-pancreas-diabetes/633888/
XX
More good news for the iLet Bionic Pancreas. A clinical trial, conducted at 16 clinical sites across the United States, enrolled 326 participants ages 6 to 79 years who had type 1 diabetes and had been using insulin for at least 1 year.
Participants were randomly allocated to a treatment group using the bionic pancreas or a standard-of-care control group that continued with their pre-trial method of glucose monitoring and insulin dosing.
In participants using the bionic pancreas, A1C improved from 7.9% to 7.3%, yet remained unchanged among the control group. The iLet doesn’t use carb counting – just meal announcements and it sets basal rates with just the user’s body weight. It’s currently in front of the US FDA, awaiting approval.
XX
Insulet issued an urgent medical device correction on Monday related to battery problems with a component of its Omnipod DASH system.
The device uses a wearable insulin pod that’s controlled by a personal diabetes manager (PDM), a smartphone-like device that does the calculations for bolus insulin doses.
Insulet plans to replace the PDMs for all of its current Omnipod DASH users globally, incurring an aggregate charge of $35 million to $45 million, J.P. Morgan Analyst Robbie Marcus wrote in a Monday research note.
Insulet said it received reports of some Omnipod DASH users having battery problems with their PDM devices, including the battery swelling, fluid leaking from the battery, and in rare cases, extreme overheating. In a letter to users, the company said it plans to ship updated devices to all current Omnipod DASH customers in the coming months.

The battery issue applies to all of Insulet’s Omnipod DASH PDMs, but the likelihood of problems may increase if the device has been in use longer than 18 months. Charging the device to a full battery and leaving it on the charger overnight also increases the risk.

So far, Insulet said it has not received reports of any injuries related to the battery issues.

The company advised patients to monitor their PDMs for battery problems, including a bulging back cover and the device losing its charge very quickly, overheating or emitting an odor.

If patients notice any of these problems, they should not charge the device, stop using the system and switch to a backup insulin plan as soon as they can. Users can also contact Insulet for a temporary replacement device.

https://www.medtechdive.com/news/insulet-battery-problems-omnipod-dash/634275/
XX
MDT) announced today that it introduced a new diabetes management program for users of the MiniMed 770G insulin pump.
The medtech giant calls the new program My Insights. It designed it exclusively for individuals using the MiniMed 770G hybrid closed-loop insulin delivery system.
Using an individual’s data, My Insight provides personalized tips, trends and reminders to help customers manage their diabetes. Its personalized recommendations come through via monthly emails with educational content. Medtronic aims to make the content relevant based on what the individual experiences.
Medtronic said it represents the first diabetes management program to go beyond “generalized tips.” Instead, it offers personalized suggestions using data from the integrated insulin pump system.
The company said it made My Insights available in the U.S. to anyone using MiniMed 770G.

https://www.drugdeliverybusiness.com/medtronic-launches-diabetes-insights-program-for-minimed-users/
XX
Some countries are seeing shortages of Ozempic, a weekly injectable meant for people with diabetes but can be prescribe off label for weight loss. Demand has gone way up since some Tik Tok and social media influencers have shared Ozempic as a weight loss drug. Diabetes groups and especially Australian advocacy groups have advised doctors to limit prescribing the drug to people with Type 2 diabetes.

https://www.abc.net.au/news/2022-10-17/ozempic-weight-loss-demand-type-2-diabetes-drug-shortage/101542226
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX

XX
XX
New research shows an older drug for type 2 might help reduce the risk for dementia. People with diabetes are at higher risk of developing dementia. These researchers looked though 500-hundred thousand past medical records and found that an older class of type 2 diabetes medication known as glitazones helps reduce a person’s dementia risk by 22%. These reerahres say its very promising but they want to see more real world study and also combine glitazones with other types of treatments
https://www.medicalnewstoday.com/articles/type-2-diabetes-drug-may-help-lower-dementia-risk-by-22
XX
On the podcast next week.. Kerri Sparling from SixUntilMe
The past episode was all about teens and type 1 – a deep dive into why teen retreats work from the people who organize a great one.. and how adults with type 1 still use the lessons they learned as teens.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Oct 18, 2022

Who would volunteer to spend a weekend with a bunch of teens with type 1? A bunch of people who’ve been there! We’re talking about teen retreats – and what even adults can learn – about the power of connection.

Patrick Mertes has lived with type 1 since he was a child. If that name sounds remember, he’s one of the climbers from the 50-in-50 project where he and a friend climbed the highest peak in all 50 states in 50 days a couple of years back. He also runs a fantastic family and teen retreat in North Carolina.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Oct 14, 2022

It's It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: Provention Bio hopes to get FDA approval of Teplizumab next month and partners with Sanofi on this T1D prevention drug, new type 2 studies show that younger people who develop it generally have worse health outcomes, Medicare considers expanded coverage of CGMs and more

Learn more about the T1D Exchange: www.T1Dexchange.org/Stacey 

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Provention Bio partners with Sanofi to help bring teplizumab to market. Teplizumab isn’t yet approved, the FDA is expected to give it the thumbs up later this year.. this is the drug shown to prevent type 1 diabetes for up to three years. Among other things, Sanofi will get exclusive global marketing rights for the drug. The FDA had asked for more information the last time teplizumab was up for approval.. the three month period for that closes in November.. and a ruling is expected then.
https://www.fiercepharma.com/pharma/proventions-regulatory-odyssey-diabetes-nears-its-end-company-taps-sanofi-marketing-assist
XX
New research has found that the age at which people are diagnosed with type 2 diabetes is associated with a higher risk of developing serious complications.
The study, which was published in JAMA Network Open, analyzed health data from more than 36,000 Americans aged 50 and above.
The researchers found that those who were diagnosed with type 2 diabetes between the ages of 50 and 59 had “elevated risks” of heart disease, stroke, disability, cognitive impairment, and early death. But when people were diagnosed with diabetes later in life, the risks were reduced.1 No obvious reason for that.. but the researchers say it does point to the need for more screening and better prevention and treatment.
https://www.verywellhealth.com/type-2-diabetes-diagnosis-age-6747897
XX
The Centers for Medicare and Medicaid Services has proposed new draft coverage guidelines for continuous glucose monitors.
Under the proposal, the CMS would cover CGMs for diabetes patients who are treated with insulin or “have a history of problematic hypoglycemia,” as defined by the frequency or severity of low blood sugar events, seemingly regardless of whether they have Type 1 or 2 diabetes.
Analysts at J.P. Morgan said the proposal reads “very favorably” for Abbott and Dexcom, leading CGM manufacturers that are targeting the “massive and highly under-penetrated Type 2 market opportunity.”
https://www.medtechdive.com/news/dexcom-abbot-CGM-diabetes-coverage/633577/
XX
Mark cuban’s Cost Plus Drugs has joined with
@RocheDiabetesUS
to provide our patients with their line of Accu-ChekⓇ test strips, lancets, & meters!

This partnership will allow anyone to access what they need to check their blood sugar, at a low price.
XX
Researchers who study Type 2 diabetes have reached a stark conclusion: There is no device, no drug powerful enough to counter the effects of poverty, pollution, stress, a broken food system, cities that are hard to navigate on foot and inequitable access to health care, particularly in minority communities. This is a long and complicated article published in the New York Times.. I’ll link it up and I urge you to read it. I can’t really to it justice in a short excerpt here.
“Our entire society is perfectly designed to create Type 2 diabetes,” said Dr. Dean Schillinger, a professor of medicine at University of California, San Francisco. “We have to disrupt that.”
Dr. Schillinger and nearly two dozen other experts laid out a road-map for doing so earlier this year in a comprehensive national report to Congress on diabetes, the first of its kind since 1975.
It calls for reframing the epidemic as a social, economic and environmental problem, and offers a series of detailed fixes, ranging from improving access to healthy food and clean water to rethinking the designs of communities, housing and transportation networks.

https://www.nytimes.com/2022/10/05/health/diabetes-prevention-diet.html
XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
The Diabetes Design initiative is looking for college age people with type 1 to help them design the ultimate alarm for an extreme low. I’ll put the contact info in the show notes, along with a link to the website. By the way, I had never heard of the Diabetes Design Initiative but boy do I know these names and you probably do too. Ben West, Dana Lewis and a few others from the history of we are not waiting
http://ddi.ucsd.edu/about.html
Grace Zheng gzheng@ucsd.edu
XX
On the podcast next week.. teens and type 1 – a deep dive into why teen retreats work from the people who organize a great one.. and how adults with type 1 still use the lessons they learned as teens.
This past episode is all about Dexcom design.
Listen wherever you get your podcasts
Hey for you parents, we’ve got a webinar on Halloween, link in the show notes and on my social media.
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Oct 11, 2022

We're taking a look at the design decisions that go into diabetes technology, specifically Dexcom’s G7. Beyond the accuracy and interoperability we all want, they also look at things like dexterity, feel and hand strength. Alex Diener is Dexcom’s Senior Director of Global Product Design. He lives with type 1 and he shared a lot of the behind the scenes thought process that’s gone into the design of the G7 sensor and transmitter and the apps that go along with it.

This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

Halloween webinar for parents: https://us02web.zoom.us/webinar/register/WN_0Xaaj9hoR-u96Kxm-OjfSQ

Moms' Night Out event: https://diabetes-connections.com/diabetes-connections-presents-moms-night-out/

Check out Stacey's books and use promo code "Spooky" to save $3!

More about Dexcom:

Our interviews with CEO Kevin Sayer: https://diabetes-connections.com/?s=sayer

Our interviews with COO Jake Leach: https://diabetes-connections.com/?s=leach

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Oct 7, 2022

It’s “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: Michigan joins California in exploring producing and distributing insulin made in-state, new study looks at why girls have a harder time with T1D than boys, weekly basal insulin moves forward, Dexcom puts G7 in wider release (but not yet in the US) and more!

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days.
XX
In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population.
https://t1dexchange.org/stacey/
XX
Michigan following California when it comes to exploring making and distributing insulin. Governor Gretchen Whitmer signed an executive directive this week to establish a Michigan-based insulin manufacturing facility, and facilitate the development, in conjunction with a partner or partners, of a low-cost insulin product for distribution in Michigan. Whitmer already announced a plan to cap insulin costs in her State of the State address in January.
https://michiganadvance.com/blog/whitmer-signs-directive-seeking-to-lower-insulin-costs-wins-bipartisan-praise/
XX
Novo Nordisk plans to move forward with its once a week insulin icodec. Recent studies show it worked as well or better than daily basal insulin, reducing A1C after 52 weeks.

Novo Nordisk’s ONWARDS program for once-weekly insulin icodec comprises six phase 3a global clinical trials, including a trial with RWE involving more than 4,000 adults with type 1 or type 2 diabetes.

It is expected that Novo Nordisk will file for regulatory approval of the once-weekly insulin icodec in the first half of 2023 in the US, the EU, and in China.
There is a separate and additional study for people with type 1 – looking at weekly insulin icodec wth mealtime insulin. That’s expected to conclude in about six months.
https://pharmaphorum.com/news/novo-nordisk-achieve-headline-results-with-icodec-insulin/
XX
Big new study shows that girls tend to have more serious issues with type 1 diabetes than boys. This is physical, quantifiable stuff, including higher blood sugar levels, weight issues, and higher cholesterol. This was a review of 90 previous studies at Amsterdam University Medical Centers. that women and girls have typically not received as much attention as study subjects as men. These researchers say more study is needed including finding ways to help doctors treat girls with type I diabetes differently than boys

https://www.healthline.com/health-news/why-type-1-diabetes-can-be-tougher-on-girls-than-boys
XX
Alarming new study says that cases of type 1 worldwide could double by 2040. Tracking has improved in recent years, but Type 1 diabetes is underrepresented. In addition, because many countries don’t collect Type 1 diabetes data, the numbers have historically skewed toward North America and Europe. About 175,000 people worldwide died because of Type 1 diabetes in 2021, they believe, and 63 to 70 percent of the deaths in those under age 25 occurred because the disease wasn’t diagnosed. This study is in the Lancet Diabetes and Endocrinology
https://www.washingtonpost.com/health/2022/10/03/diabetes-type-one-surge/
XX
Big new study looking at which drugs paired with Metformin work the best for type 2. The trial was conducted at 36 study centers nationwide with more than 5000 people. Three groups took metformin plus a medicine that increased insulin levels: sitagliptin or Januvia, liraglutide or Victoza, or glimepiride or Amaryl. The fourth group took metformin and a long acting insulin.
After about five years of follow-up, the researchers found that all four drugs improved blood glucose levels when added to metformin. But those taking metformin plus liraglutide or the long-acting insulin achieved and maintained their target blood levels for the longest time. The effects of treatment did not differ with age, sex, race, or ethnicity.
However, none of the combinations overwhelmingly outperformed the others.
https://www.nih.gov/news-events/nih-research-matters/popular-diabetes-drugs-compared-large-trial
XX
Dexcom’s G7 is getting a wider rollout: the United Kingdom, Ireland, Germany, Austria and Hong Kong, with launches in New Zealand and South Africa in the coming weeks. I’ll link up the promotional video.. no news yet from the US FDA on when the G7 will be approved in the US. I am talking to Dexcom’s Senior Director of Global Product Design for Tuesday’s podcast episode.
https://www.youtube.com/watch?v=dYqNUf0paAU
XX
Tandem’s t:connect mobile app is now compatible with the latest iOS operating system on version 2.3 of the t:connect mobile app. Until this update, you could lose the mobile bolus if you updated your phone. Tandem also added a new iPhone and nine new android devices to their compatibility list. We’ll link that up in the show notes.
: https://www.tandemdiabetes.com/.../device-compatibility

XX
Back to the news in a moment but first..
The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy.
The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey
XX
The College Diabetes Network announces a name change – they’ll now be known as the Diabetes Link. The groups says this new name reflects a commitment to expand support to the larger young adult diabetes community, whatever the type of diabetes they live with and whether they’re in school or in the workforce. Currently, there are 3 million young adults (ages 17-30) living with diabetes in the U.S. and that number continues to increase every day. The Diabetes Link is the only national organization that focuses specifically on people in their teens and twenties, in recognition that this time of their lives is full of enough change and challenges without a chronic disease added to the mix.
XX
And finally, another zoo animal with a CGM. Tiana is a lemur in New Zeleand. The zoo’s education officer, has diabetes and recommended the Dexcom for the lemur. Interestingly, they aren’t using insulin here, but rather a hypoglycemia medication and are altering the lemur’s diet. Apparently lemurs are prone to something more like type 2 diabetes due to some iron issues or if they eat too much sugar, but Tiana’s case more resembles type 1.
https://www.stuff.co.nz/national/130016440/meet-tiana-the-diabetic-lemur-with-a-glucose-monitor-stuck-to-her-back#:~:text=Hamilton%20Zoo%20resident%20lemur%2C%20Tiana,with%20diabetes%20in%20the%20zoo.&text=Zoo%20vet%20Tori%20Turner%20says,Hamilton%20has%20joined%20the%20club.
XX
On the podcast next week.. Dexcom’s Senior Director of Global Product Design – Very We’ll talk about what goes into designing a comletley new product like the G7. He lives with type 1 himself.
This past episode is all about how diabetes communities around the world stayed connected during the early days of the pandemic,
Listen wherever you get your podcasts
Hey for you parents, we’ve got a webinar on Halloween, link in the show notes and on my social media.
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Oct 4, 2022

Many of you tuned in virtually to EASD or maybe you were lucky enough to travel there! There was one talk at the European Association for the Study of Diabetes that really got my attention: the #dedoc° symposia “What we wish you knew — and why” which featured advocates speaking on topics that are relevant to people living with diabetes. The topic for this one is: Novel forms of online peer support developed during COVID; how did communities around the world stay connected?

#dedoc° was founded in 2012 by Bastian Hauck, who created the Twitter hashtag #dedoc to host weekly TweetChats for the German chapter of the Diabetes Online Community. It acted as a catalyst to grow a small group of diabetes bloggers into one of Europe’s strongest patient advocacy and peer support communities.

This is an excerpt from the symposium – you can watch the entire thing including the Q&A at the end – at www.dedoc.org/symposium.

Speakers:

Renza Scibilia,  Diabetes Australia

Andrea Limbourg, France

Jeff Hitchcock, Children with Diabetes, USA

Salih Hendricks, South Africa

Tom Dean, UK, Twitter DiabetesChat

Check out Stacey's book: The World's Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here

Episode Transcription Below (or coming soon!)

Please visit our Sponsors & Partners - they help make the show possible!

*Click here to learn more about OMNIPOD*

*Click here to learn more about AFREZZA*

*Click here to learn more about DEXCOM*

1